Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 3,387 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Advanced Solid Neoplasm Clear all

Conditions: Neoplasms, Liver Metastases
Interventions: EZN-2968; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neoplasms
Interventions: Cetuximab + Erlotinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions: Biopsy Procedure, Biospecimen Collection, Crizotinib, Radiologic Examination; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Solid Tumors
Interventions: BI 1821736; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: New Haven, Connecticut • San Antonio, Texas

Conditions: Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Malignant Mesothelioma, Ovarian Cancer, Pancreatic Cancer, Primary Peritoneal Cavity Cancer
Interventions: SS1(dsFv)-PE38 immunotoxin; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 2
States / cities: Bethesda, Maryland • Winston-Salem, North Carolina

Conditions: Locally Advanced/Metastatic Solid Tumors
Interventions: HY-0102; Drug
Lead sponsor: Shanghai HyaMab Biotech Co.,Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Orlando, Florida • Las Vegas, Nevada • Tyler, Texas

Conditions: Cancer, Neoplasms
Interventions: GSK2820151; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Detroit, Michigan • Nashville, Tennessee

Conditions: Cancer
Interventions: IDE574, Fulvestrant injection; Drug
Lead sponsor: IDEAYA Biosciences; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 18
States / cities: Santa Monica, California • New Haven, Connecticut • Plantation, Florida + 13 more

Conditions: Locally Advanced Solid Tumor
Interventions: OBI-999; Drug
Lead sponsor: OBI Pharma, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: La Jolla, California • New York, New York • Germantown, Tennessee + 1 more

Conditions: Advanced Solid Tumor, Malignant Solid Tumor
Interventions: Ifinatamab deruxtecan (I-DXd); Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 10
States / cities: Denver, Colorado • Sarasota, Florida • Boston, Massachusetts + 6 more

Conditions: Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Bile Duct Cancer, Gall Bladder Cancer, Gall Bladder Carcinoma
Interventions: certepetide, Durvalumab, Cisplatin, Gemcitabine, FOLFOX regimen, Placebo; Drug
Lead sponsor: Lisata Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 19
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more

Conditions: Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Cancer, Ovarian Cancer, Papillary Thyroid Cancer, Melanoma, Colorectal Adenocarcinoma
Interventions: CM-24 and Nivolumab - Dose Escalation, CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion, CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion, Nivolumab and Nal-IRI/5-FU/LV - Expansion; Drug
Lead sponsor: Famewave Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Scottsdale, Arizona • Aurora, Colorado • New Haven, Connecticut + 2 more

Conditions: Breast Cancer, Non Small Cell Lung Cancer, GastroEsophageal Cancer, Bladder Cancer
Interventions: ADCT-502; Drug
Lead sponsor: ADC Therapeutics S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Palo Alto, California • Buffalo, New York • New York, New York + 1 more

Conditions: Solid Cancers
Interventions: Atezolizumab, Emactuzumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 5
States / cities: New Haven, Connecticut • Boston, Massachusetts • New York, New York

Conditions: Solid Tumors
Interventions: BI 770371, ezabenlimab; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Sarasota, Florida • Hackensack, New Jersey

Conditions: Advanced Malignant Solid Neoplasm, Estrogen Receptor Positive, HER2/Neu Positive, Postmenopausal, Premenopausal, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Refractory Breast Carcinoma, Refractory Hormone Receptor Positive Breast Carcinoma, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Everolimus, Laboratory Biomarker Analysis, Letrozole, Trastuzumab; Drug · Other · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 5
States / cities: Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more

Conditions: Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer
Interventions: LYL845; Biological
Lead sponsor: Lyell Immunopharma, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 18
States / cities: Sacramento, California • Santa Monica, California • Stanford, California + 14 more

Conditions: Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: cetuximab, bortezomib; Biological · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Neoplasms, Breast Neoplasms
Interventions: Xentuzumab, Abemaciclib, Letrozole, Anastrozole, Fulvestrant; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 6
States / cities: Santa Monica, California • New Haven, Connecticut • Miami, Florida + 3 more

Conditions: Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Interventions: Carboplatin, Paclitaxel, Sapanisertib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Colorectal Carcinoma, Glioblastoma Multiforme
Interventions: ABBV-221; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Boston, Massachusetts • San Antonio, Texas

Conditions: Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma
Interventions: PF-08046050, bevacizumab, 5-Fluorouracil (5-FU), Oxaliplatin, Leucovorin (LV); Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 914 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 21
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 13 more

Conditions: Breast Cancer, Gastric/Gastroesophageal Junction Cancer
Interventions: KN026; Drug
Lead sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: intoplicine; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 2
States / cities: Fort Sam Houston, Texas • San Antonio, Texas

Search by objective public record fields.

A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases

Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer

Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors

HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours

Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors

Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors

Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors

A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

A Study to Investigate LYL845 in Adults With Solid Tumors

Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors

A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer

Chemotherapy in Treating Patients With Advanced or Metastatic Solid Tumors